Grufity logoGrufity logo

MRTX

92.75USD-3.50(-3.64%)Market Closed

Mirati Therapeutics Inc

Market Summary

USD92.75-3.50Market Closed
-3.64%

MRTX Alerts

MRTX Stock Price

RSI Chart

Valuation

Market Cap

3.8B

Price/Earnings

-5.86

Price/Sales

917.1

Price/Cashflow

-7.72

MarketCap/EBT

-6.05

Price/Sales

Profitability

EBT Margin

-17345.88%

Return on Equity

-57.96%

Return on Assets

-50.36%

Fundamentals

Revenue

Revenue Y/Y

-92.44%

Revenue Q/Q

1.29%

Earnings

Earnings (TTM)

-738.0M

Earnings Y/Y

-116.8%

Earnings Q/Q

1.63%

Price Action

52 Week Range

32.96154.17
(Low)(High)

Last 7 days

-2.4%

Last 30 days

48.1%

Last 90 days

18.8%

Trailing 12 Months

-29.8%

Financial Health

Current Ratio

10.1

Investor Care

Shares Dilution (1Y)

11.14%

Diluted EPS (TTM)

-13.43

Peers (Alternatives to Mirati Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
261.0B
57.8B
13.24% 45.49%
20.65
4.55
4.80% 77.95%
224.2B
1.2B
13.13% -41.64%
-111.81
209.81
17.64% -65.25%
81.0B
14.2B
3.50% 20.88%
14.24
5.69
14.88% -8.36%
80.6B
8.7B
3.66% 57.19%
24.61
9.26
22.03% 50.41%
25.2B
960.9M
9.35% 28.19%
-21.28
26.18
28.24% -41.08%
10.6B
1.9B
9.82% 47.16%
16.75
5.91
12.37% 52.98%
10.1B
876.0M
11.31% 51.76%
-19.93
12.09
35.70% -47.34%
MID-CAP
4.1B
-
-3.30% 6.13%
-18.85
63.29
26.15% -23.38%
3.8B
-
48.10% -29.78%
-5.86
917.1
-74.20% -52.72%
3.2B
272.3M
6.14% -50.33%
-4.51
13.74
-18.36% -74.56%
2.9B
334.3M
-1.03% -49.23%
-5.64
8.54
-6.98% -43.97%
SMALL-CAP
1.5B
191.8M
27.64% 144.62%
26.77
8.56
43.59% 60.82%
1.3B
504.0K
12.76% -3.22%
-4.91
2.5K
-66.53% -10.64%
306.1M
66.9M
42.27% -60.18%
-1.4
4.57
-43.57% -69.06%
16.0M
-
3.64% -84.06%
-0.46
19.11
-77.61% 5.14%

Financials for Mirati Therapeutics

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
RevenueNaN%nullnullnullnullnull
Operating Expenses5.7%756,742,000716,160,000697,779,000645,273,000555,942,000
  S&GA Expenses13.7%212,512,000186,897,000162,280,000136,679,000118,482,000
  R&D Expenses2.8%544,230,000529,263,000535,499,000508,594,000437,460,000
Earnings Before Taxes-62.6%-578,485,000.00-355,684,000.00
Net Income-14.5%-738,012,000.00-644,505,000.00-634,490,000.00-581,784,000.00-483,251,000.00
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets1.8%1,3031,2801,4211,5891,253
  Current Assets1.9%1,2261,2031,3431,5081,172
    Cash Equivalents12.5%299266305413243
  Net PPE4.3%1817171614
Liabilities3.7%174168172192169
  Current Liabilities6.6%127119124144122
Shareholder's Equity1.5%1,1291,1121,2491,3971,084
  Retained Earnings-8.4%-2,250.41-2,076.85-1,900.41-1,712.02-1,512.40
  Additional Paid-In Capital6.3%3,3863,1853,1453,1002,587
Accumulated Depreciation-3----
Shares Outstanding3.6%5856565552
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-18.6%-579.75-488.98-438.85-388.80-327.24
  Share Based Compensation11.3%158142132114101
Cashflow From Investing75.3%-4.33-17.57-83.82-588.90-477.40
Cashflow From Financing30.3%640491498505916

Risks

What is the probability of a big loss on MRTX?

99.2%


Probability that Mirati Therapeutics stock will be more than 20% underwater in next one year

85%


Probability that Mirati Therapeutics stock will be more than 30% underwater in next one year.

63.9%


Probability that Mirati Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does MRTX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Mirati Therapeutics was unfortunately bought at previous high price.

Returns

Cumulative Returns on MRTX

89.5%


10-Year Cumulative Returns

15.0%


7-Year Cumulative Returns

41.9%


5-Year Cumulative Returns

-2.8%


3-Year Cumulative Returns

What are the long-term rolling returns for MRTX?

FIve years rolling returns for Mirati Therapeutics.

Which funds bought or sold MRTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-21
Parallax Volatility Advisers, L.P.
REDUCED
-57.01
-2,799,000
2,265,000
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-2.14
63,000
3,530,000
0.01%
2022-11-21
FourThought Financial, LLC
UNCHANGED
-
1,000
35,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-56,000
-
-%
2022-11-15
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
ADDED
0.79
70,000
1,508,000
0.01%
2022-11-15
CASTLEARK MANAGEMENT LLC
NEW
-
1,715,000
1,715,000
0.10%
2022-11-15
ALLIANCEBERNSTEIN L.P.
REDUCED
-16.54
-332,000
2,192,000
-%
2022-11-15
ALGERT GLOBAL LLC
ADDED
66.14
577,000
1,369,000
0.08%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
ADDED
1,212.24
4,047,090
4,366,960
0.01%
2022-11-15
Neuberger Berman Group LLC
REDUCED
-3.44
6,000
1,282,000
-%

1–10 of 44

Latest Funds Activity

Are funds buying MRTX calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own MRTX

Mirati Therapeutics News

Marketscreener.com

Mirati Therapeutics Says Phase 3 Trial Assessing Lung Cancer Combination Therapy to Advance to Final Analysis.3 days ago

GuruFocus.com

MRTX Fair Value

Recent SEC filings of Mirati Therapeutics

View All Filings
Date Filed Form Type Document
Nov 28, 2022
4
Insider Trading
Nov 08, 2022
8-K
Current Report
Nov 08, 2022
4
Insider Trading
Nov 08, 2022
3
Insider Trading
Nov 08, 2022
10-Q
Quarterly Report
Sep 09, 2022
4
Insider Trading
Sep 08, 2022
8-K
Current Report

Latest Insider Trading transactions for MRTX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-28
BAUM CHARLES M
ACQUIRED
1,205,750
17.41
69,256
President,Founder,Head of R&D
2022-11-28
BAUM CHARLES M
SOLD
-6,925,600
100
-69,256
President,Founder,Head of R&D
2022-11-07
Sandler Alan B.
ACQUIRED
-
-
40,000
Chief Medical Officer
2022-09-07
Christensen Jamie
ACQUIRED
-
-
19,149
EVP, Chief Scientific Officer
2022-08-12
CARTER BRUCE L A
SOLD
-854,899
85.4899
-10,000
-
2022-08-12
CARTER BRUCE L A
ACQUIRED
270,000
27
10,000
-
2022-06-01
Stelzer Laurie
ACQUIRED
-
-
57,798
CFO
2022-05-23
Christensen Jamie
SOLD
-39,649
63.54
-624
EVP, Chief Scientific Officer
2022-02-11
FUCHS HENRY J
SOLD
-1,161,720
105.611
-11,000
-
2022-02-11
FUCHS HENRY J
ACQUIRED
225,940
20.54
11,000
-

1–10 of 50

David D. Meek
420
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

MRTX Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue    
Total revenue$ 5,431$ 71,793$ 11,502$ 71,793
Expenses    
Research and development131,076116,109390,391354,755
General and administrative60,79835,183168,97793,144
Total operating expenses191,874151,292559,368447,899
Loss from operations(186,443)(79,499)(547,866)(376,106)
Other income (expense), net13,1362,7449,728(2,759)
Loss before income taxes(173,307)(76,755)(538,138)(378,865)
Income tax expense2543,2992543,299
Net loss(173,561)(80,054)(538,392)(382,164)
Foreign currency translation adjustment(9,485)0(9,485)0
Unrealized loss on available-for-sale investments(1)(6)(5,712)(164)
Comprehensive loss$ (183,047)$ (80,060)$ (553,589)$ (382,328)
Basic net loss per share (USD per share)$ (3.09)$ (1.55)$ (9.66)$ (7.45)
Diluted net loss per share (USD per share)$ (3.09)$ (1.55)$ (9.66)$ (7.45)
Weighted average common shares outstanding, basic (shares)56,219,41651,655,25955,747,20551,305,547
Weighted average common shares outstanding, diluted (shares)56,219,41651,655,25955,747,20551,305,547

MRTX Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets  
Cash and cash equivalents$ 298,843$ 413,083
Short-term investments902,1491,078,257
Other current assets24,79216,643
Total current assets1,225,7841,507,983
Property and equipment, net17,90015,824
Long-term investment1,8828,218
Right-of-use asset36,46037,680
Other long-term assets21,05819,049
Total assets1,303,0841,588,754
Current liabilities  
Accounts payable19,45235,163
Accrued liabilities107,534108,495
Total current liabilities126,986143,658
Lease liability44,09345,879
Other liabilities2,9512,179
Total liabilities174,030191,716
Commitments and contingencies (see Note 9)
Shareholders' equity  
Preferred stock, $0.001 par value, 10,000,000 shares authorized; none issued and outstanding at both September 30, 2022 and December 31, 202100
Common stock, $0.001 par value; 100,000,000 authorized; 57,568,769 and 55,356,904 issued and outstanding at September 30, 2022 and December 31, 2021, respectively5855
Additional paid-in capital3,385,5393,099,937
Accumulated other comprehensive (loss) income(6,129)9,068
Accumulated deficit(2,250,414)(1,712,022)
Total shareholders' equity1,129,0541,397,038
Total liabilities and shareholders' equity$ 1,303,084$ 1,588,754